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FMR1
COMPLEX GENETIC ARCHITECTURE IN
AUTISM
Autism spectrum disorder (ASD) encom-
passes a range of early-onset neurode-
velopmental disorders characterized by
impaired social interactions and commu-
nications, together with repetitive stereo-
typic behaviors (MIM20895; DSM5). Indi-
viduals with ASD can display a broad clin-
ical profile ranging in symptom severity
and comorbidities. A strong genetic com-
ponent underlying ASD has been firmly
established; hundreds of genes and chro-
mosomal loci are known to be associ-
ated with the disorder and have been
cataloged in ASD-specific genetic data-
bases such as AutDB (1). The potential
genetic risk factors range from candidate
genes reported from genetic association
studies to rare, recurrent gene-disruptive
mutations identified in ASD individuals
using high-throughput technologies such
as whole exome sequencing (2). A num-
ber of recurrent copy number variants
(CNVs) that overlap with related neu-
rodevelopmental and neuropsychiatric dis-
orders such as intellectual disability and
schizophrenia have been implicated in ASD
as well. Two recent studies, in particu-
lar, provide a deeper understanding of the
complex genetic architecture of ASD. First,
a genome-wide analysis revealed shared
risk loci between five major psychiatric
disorders including ASD, attention deficit
hyperactivity disorder (ADHD), bipolar
disorder, major depressive disorder, and
schizophrenia (3). The second study exam-
ined the detailed structure of the type of
genetic liability in ASD and showed that
inherited common variants contributed to
49.4% heritability, whereas rare de novo
variants accounted for only 2.6% (4).
Despite this progress in ASD genetics, the
underlying perturbations in brain devel-
opment that contributes to the emergence
of specific symptoms along developmental
time points, whether in the first years of life
in ASD or during adolescence in the case of
schizophrenia, remains largely unresolved.
The regulatory mechanisms that orches-
trate the precise temporal and spatial pat-
terns of gene expression in the brain are
at the forefront of research for brain-based
disorders. The importance of various types
of non-coding RNAs is being increasingly
recognized in this regulatory process, with
microRNAs (miRNAs) emerging as a lead-
ing candidate. miRNAs are highly con-
served small non-coding RNAs approxi-
mately 22 nucleotides in length that reg-
ulate gene expression mostly by binding
to the 3′ UTR of target messenger RNAs
(mRNAs). miRNAs recognize their targets
primarily through complementarity with
the seed sequence at nucleotides 2–8 of
the 5′ end of the miRNA. A distinguish-
ing feature of miRNAs lies in the ability of
a single miRNA molecule to bind to the
recognition site on many mRNAs and sub-
sequently regulate their expression (5). By
this mechanism, miRNA–mRNA interac-
tions can potentially modulate expression
of hundreds of target genes and influence
the corresponding cellular networks. Any
disturbances of such a system within a neu-
ronal context could lead to altered brain
circuits and synaptic function – processes
implicated in disorders such as autism or
schizophrenia.
ROLE OF miRNAs IN PSYCHIATRIC
DISORDERS
Multiple lines of evidence implicate
involvement of miRNAs in schizophrenia.
The initial studies involved analyzing dif-
ferential miRNA expression in individuals
with schizophrenia as well as post-mortem
brains. However, direct evidence for a con-
tributory role of miRNAs comes from
genetic studies. First, the 22q11.2 chromo-
somal locus, a region in which deletions
are strongly associated with schizophrenia
risk, contains the gene DGCR8 (DGCR8
microprocessor complex subunit), one of
the components of the nuclear miRNA
processing complex. In a 22q11.2 dele-
tion mouse model, haploinsufficiency of
DGCR8 resulted in the down-regulation
of a specific subset of mature miRNAs
involved in regulation of synaptic plastic-
ity (6). Moreover, a recent investigation of
patients with 22q11.2 deletion syndrome
found reduced DGCR8 expression and dys-
regulated miRNA expression in periph-
eral blood leukocytes compared to con-
trols (7). Duplications within the 22q11.2
locus containing DGCR8 have been iden-
tified as a risk factor for ASD. The local-
ization of DGCR8 within an ASD sus-
ceptibility loci and its recently identified
regulation by methyl CpG binding pro-
tein 2, the protein encoded by the ASD-
associated gene MECP2, strongly suggests
that a possible link between the role of
this gene in miRNA processing and ASD
pathogenesis (8). Perhaps the strongest
evidence for a contributory role of miR-
NAs in schizophrenia come from a large
GWAS study, where a SNP within an intron
of the primary transcript of miR-137
located at chromosome 1p21.3 exceeded
the threshold for genome-wide significance
(P = 1.6× 10−11) (9). Interestingly, miR-
137, which is transcribed from miR-137,
was recently shown to directly interact
with the RAR-related orphan receptor A
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FIGURE 1 | Bridging the gap: a central role for miRNA in FMR1 and MET crosstalk. FMRP, the
protein encoded by the FMR1 gene, binds to miRNA processing complexes. In FMR1 knockout mice,
miRNA expression is significantly up-regulated. In particular, miR-34a, miR-34b, and miR-34c show an
absolute fold increase of 41×, 144×, and 83×, respectively. Under normal conditions, the miR-34 family
down-regulates MET expression via binding to the 3′ UTR. FMR1 knockout mice display lower MET
expression, resulting from the increased ubiquity of miRNAs. Both FMR1 and MET have been scored in
the SFARI Gene Scoring module (https://gene.sfari.org/autdb/GS_Home.do). FMR1 is classified as a
syndromic ASD gene due to the prevalence of ASD in individuals with fragile X syndrome. MET is
classified as a category 2 gene (strong ASD candidate gene) based on replication of genetic association
with ASD in multiple independent population cohorts.
(RORA) gene, an ASD candidate gene,
and potentially interact with a number of
additional ASD-associated genes (10).
EVIDENCE OF miRNA DYSREGULATION
IN AUTISM
A number of studies have focused on
alteration of miRNA expression pat-
terns in individuals with ASD in recent
years. Expression profiling studies in post-
mortem brain of individuals with ASD
have implicated a number of miRNAs
with roles in neurogenesis and plasticity.
In a case–control study, Abu-Elneel et al.
screened the expression of 466 human
miRNAs in the post-mortem cerebellar
cortex of 13 individuals with ASDs and
an equal number of controls. A total of
28 miRNAs out of 277 were differentially
expressed in at least 1 of the autism sam-
ples compared to the non-autism controls
(11). However, no specific miRNA was
uniformly dysregulated across this post-
mortem sample set. Using lymphoblastoid
cell line (LCL) samples, Talebizadeh et al.
evaluated miRNA profiles in 6 individuals
with autism compared to matched controls
and found altered expression in 9 of the
470 miRNAs in autism samples (12). In
an independent study using LCL samples
from ASD individuals, 43 miRNAs were
found to be differentially expressed in ASD
individuals relative to controls (13). Net-
work analysis of target genes from dysreg-
ulated miRNAs predicted important path-
ways involved in nervous system develop-
ment and plasticity. A recent study using
serum samples from 55 individuals with
ASD and 55 age- and sex-matched control
subjects identified 13 miRNAs that were
differentially expressed in ASD individuals
compared to the controls (14). However, a
consistent view of miRNA dysregulation in
ASD is yet to emerge, as only a few overlap-
ping differential miRNA profiles have been
identified among these studies.
SYNDROMIC ASD GENES AS
REGULATORS OF miRNA BIOGENESIS
Autism develops as a co-morbid condition
in many established single-gene disorders
such as fragile X syndrome (MIM 300624),
Rett syndrome (MIM 312750), and tuber-
ous sclerosis 1 and 2 (MIM 191100 and
MIM 613254), which are caused by muta-
tions in the fragile X mental retardation
1 (FMR1) gene, the methyl CpG binding
protein 2 (MECP2) gene, and the tuberous
sclerosis 1 (TSC1) and tuberous sclerosis
2 (TSC2) genes, respectively. Interestingly,
two genes associated with syndromic ASD,
FMR1, and MECP2, have direct links to
miRNA biogenesis. The FMR1 encoded
protein, FMRP, is a well known sequence-
specific RNA binding protein and also
interacts with the components of the
miRNA processing complex with a likely
role at the miRNA maturation step (15,
16). While MECP2 is known as a transcrip-
tional repressor, a recent report by Cheng
et al. showed that MECP2 suppresses gene
expression at the post-transcriptional level
by directly interfering with the assembly of
the miRNA processing complex (8). Both
FMR1 and MECP2 are intensely studied
by the ASD research community regard-
ing their involvement in biochemical path-
ways, synaptic function, and circuits related
to ASD. Importantly, 25% of the affected
individuals also develop ASD. Loss of func-
tion mutations in MECP2 is the primary
cause of Rett syndrome with features of
ASD; however, duplications of MECP2-
containing loci have been linked to ASD
too (17).
REGULATION OF MET BY miR-34
FAMILY OF miRNAs
Although implicated in numerous human
cancers, MET receptor tyrosine kinase
has emerged as a strong risk gene
in ASD. A risk allele located in the
promoter region of MET that neg-
atively regulates its transcription has
been associated with ASD in indepen-
dent population cohorts (AutDB, Human
Gene module; http://autism.mindspec.
org/GeneDetail/MET#HG), providing a
functional context for its involvement
in this disorder. In a recent paper, Liu
et al. showed down-regulation of a set of
protein-coding mRNAs including MET in
the hippocampus of a fragile X mouse
model (Fmr1 KO) with a concomitant
up-regulation of several miRNAs. Further-
more, the authors showed that three of the
elevated miRNAs (miR-34b, miR-340, and
miR-148) could down-regulate a reporter
construct containing the MET 3’ UTR (18).
The miR-34 family of miRNAs is of par-
ticular interest with regards to ASD. While
this family has long been recognized in the
regulation of various cancer-related cellu-
lar processes, recent studies have reported
an important role of miR-34 in neuronal
development and neuronal disorders. In
mouse ES cells, miR-34a functions in the
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regulation of neurite outgrowth and spinal
morphology, indicating its involvement in
fundamental neuronal functions (19). Evi-
dence for a role of miR-34 in psychi-
atric disorders comes from a case–control
study of schizophrenia where miR-34a was
differentially expressed in blood samples
from schizophrenia cases (20). Involve-
ment of other members of miR-34 fam-
ily in ASD-relevant phenotypes has also
been reported. Induction of miR-34c in the
central amygdala was observed following
acute restraint stress in rodents (21). Addi-
tionally, increased expression of miR-34c
within the central amygdala led to the onset
of anxiety behavior in the same model.
In an independent study, Zovoilis et al.
showed that miR-34c functions as a nega-
tive constraint of memory consolidation in
mouse models (22). In a recent study, Dias
et al. reported a role for miR-34a within the
basolateral amygdala (BLA) in fear mem-
ory consolidation (23). Finally, miR-34b
and miR-34c were dysregulated in post-
mortem brain of individuals with early-
stage Parkinson disease and shown to play a
role in mitochondrial function and dynam-
ics and oxidative stress (24). Together, miR-
34 family members are important regula-
tors of neuronal development, plasticity,
and disease. It is worth noting that, in addi-
tion to miR-34b, miR-34a, and miR34-c
are also up-regulated in Fmr1 KO mice
(18). These members of the miR-34 fam-
ily may influence the transcription of other
ASD candidate genes similar to miR-34b
regulation of MET (Figure 1).
CONCLUSION AND FUTURE
DIRECTIONS
Despite compelling evidence for the
involvement of miRNAs during normal
brain development and neuronal disorders,
their contribution to ASD pathogenesis is
inadequately assessed to date. A systematic
identification and characterization of miR-
NAs targeting high-confidence ASD genes
is likely to shed new light into the mecha-
nisms underlying ASD – an important step
for developing better treatments for this
disorder with increasing prevalence.
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